The Pan Hellenic Congress Abstracts
001. EGFR mutations in Greek patients with lung adenocarcinoma: a multi-center study (preliminary results)
Pavlos Zarogoulidis1, Anastasios Kallianos2, Haralampos Kerasiotis2, Konstantinos Marosis3, Fotios Vlastos4, Ioannis Veldekis5, Maria Aggelidou6, Konstantinos Zarogoulidis6, Aggeliki Rapti2
1Pulmonary-Oncology, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2The Second Pulmonary Clinic, Sotiria General Hospital, Athens School of Medicine, Athens, Greece; 3The Fifth Pulmonary Clinic Sotiria Hospital, Athens 11527, Greece; 4Sotiria Hospital, University of Athens, Athens, Greece; 5Department of Respiratory and Critical Care Medicine (KAA), Sotiria Chest Hospital, Athens 11527, Greece; 6The Second Pulmonary Clinic, Sismanoglio Hospital, Athens, Greece
Background: Integration of mutational epidermal growth factor receptor (EGFR) profiling to identify driver alterations in a clinical setting, is necessary to facilitate personalized lung cancer medicine. A tumor genotyping EGFR panel was developed and the Greek Mutation Study was initiated as a prospective tumor genotyping study. This study reports the frequency of driver genetic alterations in Greek lung adenocarcinoma patients, and epidemiology correlations with EGFR genotype.
Methods: Between November 2012 and June 2014, 211 lung adenocarcinoma patients were included in this study. EGFR mutations were tested in lung cancer tissues and histologic specimen. All patients completed informed consent. The method was high resolution melting analysis (HRMA) about mutations 18-21 and further analysis with method sequencing-ABI prism 3130 sequencer (DNA). Eighteen Surgically resected tissues (8.5%), 174 tumor biopsies (82%) and 19 (9%) body cavity fluids were collected and tested for EGFR mutations. We describe clinical and epidemiological profile of EGFR positive adenocarcinoma patients.
Results: Genetic EGFR positive mutations were detected in 10.8% (24 of 221) of all patients, fifteen women and nine men. All women were nonsmokers (100%) and seven of nine (78%) men were smokers. Mean age of this group was 64.3 years old. Eighteen patients were with stage IV and rest of them IIIa. None of them was operable.
Conclusions: This is one report of tumor EGFR positive Greek patients with adenocarcinoma. These data suggest that patients profiling data using a mutational testing platform would be valuable for observation for each group of patients helping clinical doctor for further molecular-targeted therapeutics in lung cancer.
Keywords: Lung cancer; epidermal growth factor receptor (EGFR); Iressa; Tarceva
doi: 10.3978/j.issn.2072-1439.2015.AB001
Cite this abstract as: Zarogoulidis P, Kallianos A, Kerasiotis H, Marosis K, Vlastos F, Veldekis I, Aggelidou M, Zarogoulidis K, Rapti A. EGFR mutations in Greek patients with lung adenocarcinoma: a multi-center study (preliminary results). J Thorac Dis 2015;7(S1):AB001. doi: 10.3978/j.issn.2072-1439.2015.AB001
